• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Kalaris Therapeutics Inc.

    3/20/26 4:07:59 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLRS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001681782
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    KALARIS THERAPEUTICS, INC.
    SEC File Number
    001-39409
    Address of Issuer
    400 Connell Drive
    Suite 5500
    Berkeley Heights
    NEW JERSEY
    07922
    Phone
    650-249-2727
    Name of Person for Whose Account the Securities are To Be Sold
    BRETT R R HAGEN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    191512868.802292830303/20/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common07/01/2024Restricted stock vesting under a registered planIssuerCheckbox not checked1507/01/2024Services Rendered
    Common10/18/2024Restricted stock vesting under a registered planIssuerCheckbox not checked2610/18/2024Services Rendered
    Common10/01/2024Restricted stock vesting under a registered planIssuerCheckbox not checked1510/01/2024Services Rendered
    Common05/02/2024Restricted stock vesting under a registered planIssuerCheckbox not checked10505/02/2024Services Rendered
    Common02/02/2025Restricted stock vesting under a registered planIssuerCheckbox not checked10102/02/2025Services Rendered
    Common07/19/2024Restricted stock vesting under a registered planIssuerCheckbox not checked2607/19/2024Services Rendered
    Common02/16/2024Restricted stock vesting under a registered planIssuerCheckbox not checked3202/16/2024Services Rendered
    Common11/02/2024Restricted stock vesting under a registered planIssuerCheckbox not checked9411/02/2024Services Rendered
    Common03/18/2025Restricted stock vesting under a registered planIssuerCheckbox not checked109803/18/2025Services Rendered
    Common08/16/2024Restricted stock vesting under a registered planIssuerCheckbox not checked3008/16/2024Services Rendered
    Common05/16/2024Restricted stock vesting under a registered planIssuerCheckbox not checked3005/16/2024Services Rendered
    Common04/19/2024Restricted stock vesting under a registered planIssuerCheckbox not checked2604/19/2024Services Rendered
    Common07/18/2024Restricted stock vesting under a registered planIssuerCheckbox not checked2607/18/2024Services Rendered
    Common01/19/2025Restricted stock vesting under a registered planIssuerCheckbox not checked5501/19/2025Services Rendered
    Common10/19/2024Restricted stock vesting under a registered planIssuerCheckbox not checked2610/19/2024Services Rendered
    Common01/01/2025Restricted stock vesting under a registered planIssuerCheckbox not checked1401/01/2025Services Rendered
    Common11/16/2024Restricted stock vesting under a registered planIssuerCheckbox not checked3011/16/2024Services Rendered
    Common02/16/2025Restricted stock vesting under a registered planIssuerCheckbox not checked3202/16/2025Services Rendered
    Common08/02/2024Restricted stock vesting under a registered planIssuerCheckbox not checked9208/02/2024Services Rendered
    Common04/18/2024Restricted stock vesting under a registered planIssuerCheckbox not checked2604/18/2024Services Rendered
    Common04/01/2024Restricted stock vesting under a registered planIssuerCheckbox not checked1604/01/2024Services Rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/20/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Brett Roger Hagen

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $KLRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KLRS

    DatePrice TargetRatingAnalyst
    12/23/2025$19.00Buy
    Chardan Capital Markets
    11/3/2025$20.00Mkt Outperform
    Citizens JMP
    9/3/2025$23.00Strong Buy
    Raymond James
    7/23/2025$3.00Neutral
    Piper Sandler
    5/7/2025$20.00Outperform
    Leerink Partners
    4/8/2025Outperform
    William Blair
    More analyst ratings

    $KLRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Kalaris Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Kalaris Therapeutics with a rating of Buy and set a new price target of $19.00

    12/23/25 8:43:15 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Kalaris Therapeutics with a new price target

    Citizens JMP initiated coverage of Kalaris Therapeutics with a rating of Mkt Outperform and set a new price target of $20.00

    11/3/25 9:08:29 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on Kalaris Therapeutics with a new price target

    Raymond James initiated coverage of Kalaris Therapeutics with a rating of Strong Buy and set a new price target of $23.00

    9/3/25 8:38:32 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    SEC Filings

    View All

    SEC Form S-3 filed by Kalaris Therapeutics Inc.

    S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)

    4/3/26 4:19:22 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Kalaris Therapeutics Inc.

    S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)

    4/3/26 4:11:42 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Kalaris Therapeutics Inc.

    144 - Kalaris Therapeutics, Inc. (0001754068) (Subject)

    3/20/26 4:07:59 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

    Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 clinical trials by year-end 2027 Completed oversubscribed $50.0 million private placement in December 2025 $118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical stage biopharmaceutical company dedicated to the development and commercializat

    3/17/26 8:00:00 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

    BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal a

    1/28/26 4:05:00 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

    BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses. The private placement includes participation from both new and existing investors, including ADAR1 Capital Management, Coastlands Capital, Invus

    12/17/25 5:59:02 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hagen Brett R

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    3/23/26 4:05:11 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Oxtoby Andrew

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    3/20/26 4:05:07 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Gall Matthew

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    3/20/26 4:05:05 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $5,000,006 worth of shares (479,847 units at $10.42) (SEC Form 4)

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    2/17/26 8:15:32 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    Financials

    Live finance-specific insights

    View All

    Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

    TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c

    12/17/25 4:01:00 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care